Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
35.04 (1y: +70%)
Market Cap 4.23 B P/E(ttm)
Enterprise Value 3.92 B P/B 18.60
SGEN- NAS (USA)
Seattle Genetics, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$35.04
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked lower than
257732% of the 388 Companies
in the Global Biotechnology industry.

( Industry Median: 52.90 vs. SGEN: No Debt )
SGEN' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt
Equity to Asset 0.48
SGEN's Equity to Asset is ranked lower than
287356% of the 348 Companies
in the Global Biotechnology industry.

( Industry Median: 0.58 vs. SGEN: 0.48 )
SGEN' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.97
Current: 0.48
0.36
0.97
Interest Coverage No Debt
SGEN's Interest Coverage is ranked lower than
403225% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
SGEN' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 10.28
M-Score: -4.1
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -27.20
SGEN's Operating margin (%) is ranked lower than
675675% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 13.90 vs. SGEN: -27.20 )
SGEN' s 10-Year Operating margin (%) Range
Min: -9958.6   Max: -27.2
Current: -27.2
-9958.6
-27.2
Net-margin (%) -25.5
SGEN's Net-margin (%) is ranked lower than
671140% of the 149 Companies
in the Global Biotechnology industry.

( Industry Median: 13.50 vs. SGEN: -25.5 )
SGEN' s 10-Year Net-margin (%) Range
Min: -7917.2   Max: -25.5
Current: -25.5
-7917.2
-25.5
ROE (%) -23.8
SGEN's ROE (%) is ranked lower than
689654% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 9.80 vs. SGEN: -23.8 )
SGEN' s 10-Year ROE (%) Range
Min: -108.2   Max: -23.8
Current: -23.8
-108.2
-23.8
ROA (%) -11.4
SGEN's ROA (%) is ranked lower than
675675% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 6.70 vs. SGEN: -11.4 )
SGEN' s 10-Year ROA (%) Range
Min: -45.5   Max: -11.4
Current: -11.4
-45.5
-11.4
ROC (Joel Greenblatt) (%) -7368.60
SGEN's ROC (Joel Greenblatt) (%) is ranked lower than
740740% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 21.60 vs. SGEN: -7368.60 )
SGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7368.6   Max: -422.5
Current: -7368.6
-7368.6
-422.5
Revenue Growth (%) 33.1
SGEN's Revenue Growth (%) is ranked lower than
714285% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 12.40 vs. SGEN: 33.1 )
SGEN' s 10-Year Revenue Growth (%) Range
Min: 5.4   Max: 103.1
Current: 33.1
5.4
103.1
EBITDA Growth (%) -15.9
SGEN's EBITDA Growth (%) is ranked lower than
1010100% of the 99 Companies
in the Global Biotechnology industry.

( Industry Median: 11.00 vs. SGEN: -15.9 )
SGEN' s 10-Year EBITDA Growth (%) Range
Min: -23.6   Max: 13.7
Current: -15.9
-23.6
13.7
EPS Growth (%) -15.4
SGEN's EPS Growth (%) is ranked lower than
1162790% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 12.20 vs. SGEN: -15.4 )
SGEN' s 10-Year EPS Growth (%) Range
Min: -26.8   Max: 20.3
Current: -15.4
-26.8
20.3
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SGEN Guru Trades in Q2 2012

Manning & Napier Advisors, Inc 205,756 sh (New)
RS Investment Management 214,000 sh (New)
PRIMECAP Management 10,779,400 sh (+9.46%)
Columbia Wanger 8,335,000 sh (-0.98%)
» More
Q3 2012

SGEN Guru Trades in Q3 2012

Steven Cohen 28,767 sh (New)
Jim Simons 308,413 sh (New)
RS Investment Management 285,310 sh (+33.32%)
Columbia Wanger 8,335,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
PRIMECAP Management 10,754,700 sh (-0.23%)
» More
Q4 2012

SGEN Guru Trades in Q4 2012

Manning & Napier Advisors, Inc 335,080 sh (New)
RS Investment Management 392,960 sh (+37.73%)
Jim Simons 414,913 sh (+34.53%)
Columbia Wanger 8,965,304 sh (+7.56%)
PRIMECAP Management 10,523,157 sh (-2.15%)
Steven Cohen 27,493 sh (-4.43%)
» More
Q1 2013

SGEN Guru Trades in Q1 2013

Manning & Napier Advisors, Inc 492,200 sh (+46.89%)
RS Investment Management 398,920 sh (+1.52%)
Steven Cohen Sold Out
PRIMECAP Management 10,429,099 sh (-0.89%)
Columbia Wanger 8,625,000 sh (-3.8%)
Jim Simons 219,613 sh (-47.07%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2011-06-30 Add 21.21%0.05%$15 - $21.34 $ 35.3597%9572853
PRIMECAP Management 2011-03-31 Add 29.25%0.04%$13.95 - $17.23 $ 35.35129%7897953
PRIMECAP Management 2010-12-31 Add 77.8%0.06%$13.77 - $17.35 $ 35.35126%6110600
PRIMECAP Management 2010-09-30 New Buy0.09%$11.44 - $15.08 $ 35.35189%3436800
Jean-Marie Eveillard 2010-03-31 Sold Out 0.01%$9.34 - $12.59 $ 35.35226%0
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Seattle Genetics, Inc.

Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN
September 10, 2012
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Seattle Genetics Inc., Profire Energy Inc., Marriott International Inc, Express Scripts Holdings Company, Lionbridge Technologies Inc. and Repligen Corporation. Read more...

Ratios

vs
industry		 vs
history
P/B 18.60
SGEN's P/B is ranked lower than
278551% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. SGEN: 18.60 )
SGEN' s 10-Year P/B Range
Min: 1.61   Max: 19.27
Current: 18.6
1.61
19.27
P/S 19.00
SGEN's P/S is ranked lower than
255102% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 7.53 vs. SGEN: 19.00 )
SGEN' s 10-Year P/S Range
Min: 9.98   Max: 300
Current: 19
9.98
300
EV-to-EBIT 11.6
SGEN's EV-to-EBIT is ranked lower than
375939% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. SGEN: 11.6 )
SGEN' s 10-Year EV-to-EBIT Range
Min: 68.7   Max: 92.9
Current: 11.6
68.7
92.9

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 35.7
SGEN's Price/Net Cash is ranked lower than
529100% of the 189 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. SGEN: 35.7 )
SGEN' s 10-Year Price/Net Cash Range
Min: 3.5   Max: 42.2
Current: 35.7
3.5
42.2
Price/Net Current Asset Value 93
SGEN's Price/Net Current Asset Value is ranked lower than
319488% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. SGEN: 93 )
SGEN' s 10-Year Price/Net Current Asset Value Range
Min: 14.9   Max: 126.7
Current: 93
14.9
126.7
Price/Tangible Book 18.8
SGEN's Price/Tangible Book is ranked lower than
290697% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. SGEN: 18.8 )
SGEN' s 10-Year Price/Tangible Book Range
Min: 2   Max: 13
Current: 18.8
2
13
Price/Median PS Value 0.7
SGEN's Price/Median PS Value is ranked lower than
289017% of the 346 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SGEN: 0.7 )
SGEN' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 2.4
Current: 0.7
0.5
2.4
Forward Rate of Return (Yacktman) -11.06
SGEN's Forward Rate of Return (Yacktman) is ranked lower than
1492536% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. SGEN: -11.06 )
SGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.8   Max: 2.6
Current: -11.06
1.8
2.6

Business Description

Seattle Genetics, Inc. was incorporated in Delaware on July 15, 1997. Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. On August 19, 2011, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of ADCETRISTM, or brentuximab vedotin, in two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Company's proprietary technology. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has three clinical-stage ADC programs, which consist of SGN-75, ASG-5ME, and ASG-22ME, as well as several preclinical product candidates, including SGN-CD19A. The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, pre-market approval, manufacture, marketing and distribution of biopharmaceutical products.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:SGT.Germany
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: SGEN, APKT, AMRC, FNGN Oct 10 2011 
Weekly CEO Sells Highlight: WLL, PDE, HUM, SGEN Mar 20 2011 
Seattle Genetics Inc. (SGEN) President and CEO Clay B Siegall sells 200,000 Shares Mar 18 2011 
Seattle Genetics Inc. Reports Operating Results (10-Q) Nov 05 2010 
Seattle Genetics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Seattle Genetics Inc. Reports Operating Results (10-Q) May 07 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial